Objective: Assess the budgetary impact of adding erlotinib for maintenance therapy (MTx) in
advanced non-small cell lung cancer (NSCLC) from a US health plan perspective. Methods …

Objectives: A recent phase III trial showed that patients with advanced non-small cell lung
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …

BACKGROUND: Lung cancer is the most common non-skin cancer and the leading cause of
cancer death among men and women in North America. More than half of all patients …

Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …

Abstract The UK National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of …

Objective: A cost-minimisation and budget impact analysis of erlotinib versus docetaxel or
pemetrexed as second-line treatment for advanced non-small-cell lung cancer (NSCLC) …

Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line
maintenance treatment of patients with locally advanced or metastatic non-small-cell lung …

Background Platinum-doublet, first-line treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to …